This inventor holds 3 USPTO granted patents. Top assignee: Celgene Corporation. Active years: 2011-2015.
Location History:
- San Deigo, CA (US) (2011)
- San Diego, CA (US) (2014 - 2015)
Company Filing History:
Years Active: 2011-2015
Title: Helen A. Brady: Innovator in Immunomodulatory Compounds
Introduction
Helen A. Brady is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of immunomodulatory compounds, holding a total of 3 patents. Her work focuses on methods for treating disorders associated with low levels of CD59, showcasing her dedication to advancing medical science.
Latest Patents
Brady's latest patents include innovative methods using immunomodulatory compounds for modulating the level of CD59. These methods involve the administration of specific compounds, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Additionally, she has developed methods for using micro-RNA as a biomarker of immunomodulatory drug activity, which includes assessing patient compliance in treatments.
Career Highlights
Helen A. Brady is currently associated with Celgene Corporation, where she continues to innovate in her field. Her work has been instrumental in developing new therapeutic approaches that enhance patient care and treatment outcomes.
Collaborations
Brady collaborates with notable colleagues, including Kyle Chan and Gregory D. Ferguson, contributing to a dynamic research environment that fosters innovation.
Conclusion
Helen A. Brady's contributions to immunomodulatory compounds and her innovative patents reflect her commitment to improving healthcare. Her work continues to pave the way for advancements in medical treatments and patient management.